A Phase 2 interventional study of Oral EVO756 300 mg QD and Oral EVO756 50 mg BID in Chronic Inducible Urticaria, sponsored by Evommune, Inc.. Completed at 18 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by Evommune, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
Evommune, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral EVO756 300 mg QD
Drug: Oral EVO756 300 mg QD
Oral EVO756 50 mg BID
Drug: Oral EVO756 50 mg BID
Oral EVO756, 300 mg once daily
Oral EVO756 50 mg twice daily
Safety and Tolerability
Safety will be assessed by the total number of subjects with at least one TEAE
Time frame: Day 1 to Week 6
Change in Total Fric Score (TFS)
The Total Fric Score represents the total number of linear wheals with a width of ≥3 mm induced following the Fric Test, from 0 to 4; 0 representing the minimum score (better outcome), and 4 representing the maximum score (worse outcome). A complete response is equal to a response of 0, where a subject began with at least a score of 1. A partial response is equal to a decrease of at least 2 points in the score (wheals), where a subject began with at least a score of 2. Partial responders may also be considered complete responders if their final score is equal to 0.
Time frame: Day 1 to Week 4
Change in Pruritus Severity at the Provocation Test Site
The Pruritus Severity is determined based on the Pruritus Numeric Rating Scale, or P-NRS. This is an 11-point scale completed by the subject prior to and approximately 10 minutes after completion of the provocation test, where 10 represents the worst itch (maximum), and 0 represents no itch (minimum) at the site of the urticaria provocation test.
Time frame: Day 1 to Week 4
| Milestone | EVO756 300 mg QD | EVO756 50 mg BID |
|---|---|---|
| Started | 11 | 19 |
| Completed | 10 | 18 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
Safety will be assessed by the total number of subjects with at least one TEAE
| Participants with a TEAE | EVO756 300 mg QD | EVO756 50 mg BID |
|---|---|---|
| Safety and Tolerability | 3 | 7 |
The Total Fric Score represents the total number of linear wheals with a width of ≥3 mm induced following the Fric Test, from 0 to 4; 0 representing the minimum score (better outcome), and 4 representing the maximum score (worse outcome). A complete response is equal to a response of 0, where a subject began with at least a score of 1. A partial response is equal to a decrease of at least 2 points in the score (wheals), where a subject began with at least a score of 2. Partial responders may also be considered complete responders if their final score is equal to 0.
| Total Fric Score | EVO756 300 mg QD | EVO756 50 mg BID |
|---|---|---|
| Change in Total Fric Score (TFS) | -1.4 ± 1.58 | -1.5 ± 1.33 |
The Pruritus Severity is determined based on the Pruritus Numeric Rating Scale, or P-NRS. This is an 11-point scale completed by the subject prior to and approximately 10 minutes after completion of the provocation test, where 10 represents the worst itch (maximum), and 0 represents no itch (minimum) at the site of the urticaria provocation test.
| scores on a scale | EVO756 300 mg QD | EVO756 50 mg BID |
|---|---|---|
| Change in Pruritus Severity at the Provocation Test Site | -2.4 ± 2.17 | -2.1 ± 2.77 |
Collected over 6 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EVO756 300 mg QD | 0/11 (0%) | 0/11 (0%) | 3/11 (27.3%) |
| EVO756 50 mg BID | 0/19 (0%) | 0/19 (0%) | 7/19 (36.8%) |
| Event | EVO756 300 mg QD | EVO756 50 mg BID |
|---|---|---|
| Alanine Aminotransferase IncreasedInvestigations | 2/11 | 0/19 |
| Aspartate Aminotransferase IncreasedInvestigations | 2/11 | 0/19 |
| FatigueGeneral disorders | 1/11 | 0/19 |
| Hepatic CystHepatobiliary disorders | 1/11 | 0/19 |
| GastroenteritisInfections and infestations | 1/11 | 1/19 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 1/11 | 0/19 |
| Vulvovaginal Mycotic InfectionInfections and infestations | 1/11 | 0/19 |
| Back PainMusculoskeletal and connective tissue disorders | 1/11 | 0/19 |
| SciaticaNervous system disorders | 1/11 | 0/19 |
| Renal CystRenal and urinary disorders | 1/11 | 0/19 |
| Age, Categorical(Participants) | EVO756 300 mg QD | EVO756 50 mg BID | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 19 | 30 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | EVO756 300 mg QD | EVO756 50 mg BID | Total |
|---|---|---|---|
| Female | 7 | 17 | 24 |
| Male | 4 | 2 | 6 |
| Ethnicity (NIH/OMB)(Participants) | EVO756 300 mg QD | EVO756 50 mg BID | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 5 | 6 |
| Not Hispanic or Latino | 10 | 14 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2024 to primary completion in May 2025, 8 months.
Results were first posted in May 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chronic Inducible Urticaria
Evommune, Inc.